Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
The current Moderna(MRNA) stock price is $55.74, with a market capitalization of 22.01B. The stock trades at a price-to-earnings (P/E) ratio of -6.86.
On 2026-03-04, Moderna(MRNA) stock moved within a range of $51.65 to $56.60. With shares now at $55.74, the stock is trading +7.9% above its intraday low and -1.5% below the session's peak.
Trading volume for Moderna(MRNA) stock has reached 10.73M, versus its average volume of 9.42M.
The stock's 52-week range extends from a low of $22.28 to a high of $56.60.
The stock's 52-week range extends from a low of $22.28 to a high of $56.60.
MRNA News
BofA contends that Moderna’s (MRNA) settlement with Arbutus (ABUS) and Genevant (ROIV) takes “a meaningful chunk of the litigation overhang off the table,” but...
Futures are marginally higher this morning as markets react to a week of elevated geopolitical risk and see-saw headlines around the Middle East conflict. Geopo...
Moderna and Ross Stores Lead Stock Gainers on Wednesday Quick Read Moderna (MRNA) is up 8.9% on a $2.25B settlement with Arbutus (ABUS) and Roivant (ROIV), cle...
Analyst ratings
73%
of 26 ratingsMore MRNA News
Moderna (MRNA) stock is up by almost 7% in pre-market hours on Wednesday after the vaccine maker announced it had settled patent litigation with Arbutus Biophar...
Here are some of the stocks making notable moves in Wednesday's premarket action: Moderna shares are up more than 5% after the pharmaceutical company said it h...
(RTTNews) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Geneva...
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. Fo...
Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), and Arbutus Biopharma Corporation (ABUS), announced that they have entered into a $2.25 billion glob...
Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketi...
In February 2026, Moderna’s mRNA-based seasonal flu vaccine application, initially rejected by the U.S. Food and Drug Administration over trial design concerns,...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.